Company
Our mission is to create real hopes
through innovative new drug developments
through innovative new drug developments
History
- HOME
- Company
- History
2017~PRESENT
Growth and Leap of Pinotbio
-
2023
- 12
- Received the MOTIE Award for ‘2023 IP-R&D Outstanding Institution’
- 11
-
Received the KoreaBIO President’s Award for
‘2023 Bio Innovation & Growth Corporation’
- 09
- Selected for KDDF’s National Novel Drug Development Grant (ADC)
- 05
-
Selected for MOTIE’s National Research Grant for Biotech Technology
Development (ADC)
- 04
-
Strategic Investment (Lotte Biologics, KR)
Venture Capital Funding (Pre-IPO)
- 03
- Strategic Investment (Ahn-Gook Pharm, KR)
- 01
- Entered joint development of ADCs (Bridge Biotherapeutics, KR)
Passed KOSDAQ Technology Evaluation
-
2022
- 12
-
Entered joint development of next-gen ADC treatment
(Ahn-Gook Pharm, KR)
- 10
-
Strategic Investment (Celltrion, KR)
Entered into licensing agreement for the use of the PINOT-ADC™ Platform and joint development of ADCs (Celltrion, KR)
- 08
- Jointly awarded KDDF government R&D research grant for expanding the foundation of novel drug development (ProEn Therapeutics, KR)
- 06
- Entered into licensing agreement for the use of the PINOT-ADC™ Platform (ConjugateBio, USA)
- 05
- Entered additional joint development (Aptamer Group, UK)
- 02
- Entered joint development of ADCs (Hecto Healthcare, KR)
-
2021
- 06
-
Entered joint development of repebody-drug conjugate
(ProEn Therapeutics, KR)
Entered joint development of aptamer-drug conjugate
(Aptamer Group, UK)
Entered into licensing agreement for NTX-301 in non-oncology indication
(AkiraBio, USA)
- 05
-
NTX-301 Phase 1/2 clinical trial approval in Australia
(solid cancer, ovarian cancer, and bladder cancer)
- 03
- Strategic Investment (ST Pharm, KR)
- 02
- Started the clinical trial of NTX-301 (blood cancer)
-
2020
- 12
- NTX-101 Phase 1 IND approved in Korea
- 11
- Venture Capital Funding (Series C)
- 07
- Established US subsidiary (Pinotbio North America, Inc.)
- 04
- Changed company name (Bionetix Inc. → Pinotbio Inc.)
- 03
- Appointed IPO representative (NH Investment & Securities, KB Securities)
- 02
- NTX-301 Phase 1/2 (blood cancer) IND approved in the US
-
2019
- 12
-
Venture Capital Funding (Series B)
Completed the phase 1a clinical trial of NTX-301 (solid cancer) in the US
- 06
- Completed the preclinical development of NTX-101
- 04
- Completed the preclinical development of NTX-301 (blood cancer)
- 01
- Started the phase 1a clinical trial of NTX-301 (solid cancer) in the US
-
2018
- 11
- Started the preclinical development of NTX-301 (blood cancer)
- 10
-
NTX-301 Phase 1/2 (solid cancer) IND approved in US
(NCI CTEP Program)
Secured the exclusive license for NTX-301
- 09
- Venture Capital Funding (Series A)
- 02
- Research Institute established and certified
-
2017
- 12
- Started the development of PINOT-ADC™ platform
- 11
- Venture Capital Funding(2nd Seed Round)
- 06
- Started the preclinical development of NTX-301(solid cancer)
- 03
-
Venture Capital Funding(1st Seed Round)
Started the preclinical development of NTX-101
- 02
- Bionetix Inc. Established